{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T11:12:09Z","timestamp":1790507529771,"version":"4.1.0"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2016,12,1]],"date-time":"2016-12-01T00:00:00Z","timestamp":1480550400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2016,12,1]],"date-time":"2016-12-01T00:00:00Z","timestamp":1480550400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Late stage epithelial ovarian cancer has a dismal prognosis. Identification of pharmacogenomic markers (i.e. polymorphisms) to stratify patients to optimize individual therapy is of paramount importance. We here report the retrospective analysis of polymorphisms in 5 genes (\n                    <jats:italic>ATM<\/jats:italic>\n                    ,\n                    <jats:italic>ATR<\/jats:italic>\n                    ,\n                    <jats:italic>Chk1<\/jats:italic>\n                    ,\n                    <jats:italic>Chk2<\/jats:italic>\n                    and\n                    <jats:italic>CDK12)<\/jats:italic>\n                    involved in the cellular response to platinum in a cohort of 240 cancer patients with late stage ovarian cancer. The aim of the present study was to evaluate associations between the above mentioned SNPs and patients\u2019 clinical outcomes: overall survival (OS) and progression free survival (PFS). None of the\n                    <jats:italic>ATM<\/jats:italic>\n                    ,\n                    <jats:italic>ATR<\/jats:italic>\n                    ,\n                    <jats:italic>Chk1<\/jats:italic>\n                    and\n                    <jats:italic>Chk2<\/jats:italic>\n                    polymorphisms was found to significantly affect OS nor PFS in this cohort of patients. Genotype G\/G of\n                    <jats:italic>CDK12<\/jats:italic>\n                    polymorphism (rs1054488) predicted worse OS and PFS than the genotype A\/A-A\/G in univariate analysis. The predictive value was lost in the multivariate analysis. The positive correlation observed between this polymorphism and age, grade and residual tumor may explain why the\n                    <jats:italic>CDK12<\/jats:italic>\n                    variant was not confirmed as an independent prognostic factor in multivariate analysis.The importance of\n                    <jats:italic>CDK12<\/jats:italic>\n                    polymorphism as possible prognostic biomarker need to be confirmed in larger ovarian cancer cohorts, and possibly in other cancer population responsive to platinum agents.\n                  <\/jats:p>","DOI":"10.1038\/srep38142","type":"journal-article","created":{"date-parts":[[2016,12,1]],"date-time":"2016-12-01T05:34:32Z","timestamp":1480570472000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["The impact of DNA damage response gene polymorphisms on therapeutic outcomes in late stage ovarian cancer"],"prefix":"10.1038","volume":"6","author":[{"given":"F.","family":"Guffanti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Fruscio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Rulli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Damia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,12,1]]},"reference":[{"key":"BFsrep38142_CR1","doi-asserted-by":"crossref","first-page":"9","DOI":"10.3322\/caac.21208","volume":"64","author":"R Siegel","year":"2014","unstructured":"Siegel, R., Ma, J., Zou, Z. & Jemal, A. Cancer statistics, 2014. CA Cancer J Clin 64, 9\u201329 (2014).","journal-title":"CA Cancer J Clin"},{"key":"BFsrep38142_CR2","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1016\/S0140-6736(13)62146-7","volume":"384","author":"GC Jayson","year":"2014","unstructured":"Jayson, G. C., Kohn, E. C., Kitchener, H. C. & Ledermann, J. A. Ovarian cancer. Lancet 384, 1376\u20131388 (2014).","journal-title":"Lancet"},{"key":"BFsrep38142_CR3","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1016\/j.ygyno.2014.02.038","volume":"133","author":"A Davis","year":"2014","unstructured":"Davis, A., Tinker, A. V. & Friedlander, M. \u201cPlatinum resistant\u201d ovarian cancer: what is it, who to treat and how to measure benefit? Gynecol Oncol 133, 624\u2013631 (2014).","journal-title":"Gynecol Oncol"},{"key":"BFsrep38142_CR4","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.phrs.2016.01.001","volume":"106","author":"L Amable","year":"2016","unstructured":"Amable, L. Cisplatin resistance and opportunities for precision medicine. Pharmacol Res 106, 27\u201336 (2016).","journal-title":"Pharmacol Res"},{"key":"BFsrep38142_CR5","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/nrc.2015.2","volume":"16","author":"WP Roos","year":"2016","unstructured":"Roos, W. P., Thomas, A. D. & Kaina, B. DNA damage and the balance between survival and death in cancer biology. Nat Rev Cancer 16, 20\u201333 (2016).","journal-title":"Nat Rev Cancer"},{"key":"BFsrep38142_CR6","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.mrrev.2014.11.005","volume":"763","author":"B Haynes","year":"2015","unstructured":"Haynes, B., Saadat, N., Myung, B. & Shekhar, M. P. Crosstalk between translesion synthesis, Fanconi anemia network, and homologous recombination repair pathways in interstrand DNA crosslink repair and development of chemoresistance. Mutat Res Rev Mutat Res 763, 258\u2013266 (2015).","journal-title":"Mutat Res Rev Mutat Res"},{"key":"BFsrep38142_CR7","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1158\/1078-0432.CCR-07-2238","volume":"14","author":"LP Martin","year":"2008","unstructured":"Martin, L. P., Hamilton, T. C. & Schilder, R. J. Platinum resistance: the role of DNA repair pathways. Clin Cancer Res 14, 1291\u20131295 (2008).","journal-title":"Clin Cancer Res"},{"key":"BFsrep38142_CR8","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1515\/dmpt-2015-0042","volume":"31","author":"AE Rodriguez-Vicente","year":"2016","unstructured":"Rodriguez-Vicente, A. E. et al. Pharmacogenetics and pharmacogenomics as tools in cancer therapy. Drug Metabol Personal Ther 31, 25\u201334 (2016).","journal-title":"Drug Metabol Personal Ther"},{"key":"BFsrep38142_CR9","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/S0378-1119(99)00219-X","volume":"234","author":"AJ Brookes","year":"1999","unstructured":"Brookes, A. J. The essence of SNPs. Gene 234, 177\u2013186 (1999).","journal-title":"Gene"},{"key":"BFsrep38142_CR10","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1038\/35057279","volume":"409","author":"M Stoneking","year":"2001","unstructured":"Stoneking, M. Single nucleotide polymorphisms. From the evolutionary past. Nature 409, 821\u2013822 (2001).","journal-title":"Nature"},{"key":"BFsrep38142_CR11","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.2217\/14622416.8.8.1075","volume":"8","author":"AA Komar","year":"2007","unstructured":"Komar, A. A. Silent SNPs: impact on gene function and phenotype. Pharmacogenomics 8, 1075\u20131080 (2007).","journal-title":"Pharmacogenomics"},{"key":"BFsrep38142_CR12","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1038\/tpj.2013.10","volume":"14","author":"X Liu","year":"2014","unstructured":"Liu, X., Cheng, D., Kuang, Q., Liu, G. & Xu, W. Association of UGT1A1*28 polymorphisms with irinotecan-induced toxicities in colorectal cancer: a meta-analysis in Caucasians. Pharmacogenomics J 14, 120\u2013129 (2014).","journal-title":"Pharmacogenomics J"},{"key":"BFsrep38142_CR13","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1097\/FPC.0000000000000134","volume":"25","author":"JN Patel","year":"2015","unstructured":"Patel, J. N. Cancer pharmacogenomics: implications on ethnic diversity and drug response. Pharmacogenet Genomics 25, 223\u2013230 (2015).","journal-title":"Pharmacogenet Genomics"},{"key":"BFsrep38142_CR14","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1146\/annurev-med-053013-053944","volume":"66","author":"DL Hertz","year":"2015","unstructured":"Hertz, D. L. & Rae, J. Pharmacogenetics of cancer drugs. Annu Rev Med 66, 65\u201381 (2015).","journal-title":"Annu Rev Med"},{"key":"BFsrep38142_CR15","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1111\/joim.12321","volume":"277","author":"C Rodriguez-Antona","year":"2015","unstructured":"Rodriguez-Antona, C. & Taron, M. Pharmacogenomic biomarkers for personalized cancer treatment. J Intern Med 277, 201\u2013217 (2015).","journal-title":"J Intern Med"},{"key":"BFsrep38142_CR16","doi-asserted-by":"crossref","first-page":"2532","DOI":"10.1016\/j.ejca.2014.07.013","volume":"50","author":"J Robert","year":"2014","unstructured":"Robert, J., Le Morvan, V., Giovannetti, E. & Peters, G. J. On the use of pharmacogenetics in cancer treatment and clinical trials. Eur J Cancer 50, 2532\u20132543 (2014).","journal-title":"Eur J Cancer"},{"key":"BFsrep38142_CR17","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1016\/j.ctrv.2014.05.003","volume":"40","author":"S Liu","year":"2014","unstructured":"Liu, S. & Kurzrock, R. Toxicity of targeted therapy: Implications for response and impact of genetic polymorphisms. Cancer Treat Rev 40, 883\u2013891 (2014).","journal-title":"Cancer Treat Rev"},{"key":"BFsrep38142_CR18","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1016\/j.ctrv.2012.02.004","volume":"38","author":"D Borchiellini","year":"2012","unstructured":"Borchiellini, D., Etienne-Grimaldi, M. C., Thariat, J. & Milano, G. The impact of pharmacogenetics on radiation therapy outcome in cancer patients. A focus on DNA damage response genes. Cancer Treat Rev 38, 737\u2013759 (2012).","journal-title":"Cancer Treat Rev"},{"key":"BFsrep38142_CR19","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.dnarep.2015.12.009","volume":"39","author":"A Guleria","year":"2016","unstructured":"Guleria, A. & Chandna, S. ATM kinase: Much more than a DNA damage responsive protein. DNA Repair (Amst) 39, 1\u201320 (2016).","journal-title":"DNA Repair (Amst)"},{"key":"BFsrep38142_CR20","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/j.molcel.2015.10.040","volume":"60","author":"MJ O\u2019Connor","year":"2015","unstructured":"O\u2019Connor, M. J. Targeting the DNA Damage Response in Cancer. Mol Cell 60, 547\u2013560 (2015).","journal-title":"Mol Cell"},{"key":"BFsrep38142_CR21","doi-asserted-by":"crossref","first-page":"2042","DOI":"10.1158\/1078-0432.CCR-07-1520","volume":"14","author":"T Okazaki","year":"2008","unstructured":"Okazaki, T. et al. Single-nucleotide polymorphisms of DNA damage response genes are associated with overall survival in patients with pancreatic cancer. Clin Cancer Res 14, 2042\u20132048 (2008).","journal-title":"Clin Cancer Res"},{"key":"BFsrep38142_CR22","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.pharmthera.2014.12.001","volume":"149","author":"AM Weber","year":"2015","unstructured":"Weber, A. M. & Ryan, A. J. ATM and ATR as therapeutic targets in cancer. Pharmacol Ther 149, 124\u2013138 (2015).","journal-title":"Pharmacol Ther"},{"key":"BFsrep38142_CR23","doi-asserted-by":"crossref","first-page":"46","DOI":"10.4161\/cc.3.1.631","volume":"3","author":"G Damia","year":"2004","unstructured":"Damia, G. & Broggini, M. Cell cycle checkpoint proteins and cellular response to treatment by anticancer agents. Cell Cycle 3, 46\u201350 (2004).","journal-title":"Cell Cycle"},{"key":"BFsrep38142_CR24","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1016\/j.ejca.2007.05.003","volume":"43","author":"G Damia","year":"2007","unstructured":"Damia, G. & D\u2019Incalci, M. Targeting DNA repair as a promising approach in cancer therapy. Eur J Cancer 43, 1791\u20131801 (2007).","journal-title":"Eur J Cancer"},{"key":"BFsrep38142_CR25","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1038\/nature03482","volume":"434","author":"J Bartkova","year":"2005","unstructured":"Bartkova, J. et al. DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis. Nature 434, 864\u2013870 (2005).","journal-title":"Nature"},{"key":"BFsrep38142_CR26","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1038\/nature08467","volume":"461","author":"SP Jackson","year":"2009","unstructured":"Jackson, S. P. & Bartek, J. The DNA-damage response in human biology and disease. Nature 461, 1071\u20131078 (2009).","journal-title":"Nature"},{"key":"BFsrep38142_CR27","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.ejps.2016.03.025","volume":"89","author":"S Kachalaki","year":"2016","unstructured":"Kachalaki, S., Ebrahimi, M., Mohamed Khosroshahi, L., Mohammadinejad, S. & Baradaran, B. Cancer chemoresistance; biochemical and molecular aspects: a brief overview. Eur J Pharm Sci 89, 20\u201330 (2016).","journal-title":"Eur J Pharm Sci"},{"key":"BFsrep38142_CR28","doi-asserted-by":"crossref","unstructured":"Lopez-Martinez, D., Liang, C. C. & Cohn, M. A. Cellular response to DNA interstrand crosslinks: the Fanconi anemia pathway. Cell Mol Life Sci (2016).","DOI":"10.1007\/s00018-016-2218-x"},{"key":"BFsrep38142_CR29","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.canlet.2014.12.038","volume":"358","author":"H Tian","year":"2015","unstructured":"Tian, H. et al. DNA damage response\u2013a double-edged sword in cancer prevention and cancer therapy. Cancer Lett 358, 8\u201316 (2015).","journal-title":"Cancer Lett"},{"key":"BFsrep38142_CR30","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.4161\/cc.10.13.16398","volume":"10","author":"L Carrassa","year":"2011","unstructured":"Carrassa, L. & Damia, G. Unleashing Chk1 in cancer therapy. Cell Cycle 10, 2121\u20132128 (2011).","journal-title":"Cell Cycle"},{"key":"BFsrep38142_CR31","doi-asserted-by":"crossref","first-page":"e1012976","DOI":"10.1080\/23723556.2015.1012976","volume":"2","author":"G Manic","year":"2015","unstructured":"Manic, G., Obrist, F., Sistigu, A. & Vitale, I. Trial Watch: Targeting ATM-Chk2 and ATR-Chk1 pathways for anticancer therapy. Mol Cell Oncol 2, e1012976 (2015).","journal-title":"Mol Cell Oncol"},{"key":"BFsrep38142_CR32","doi-asserted-by":"crossref","first-page":"379","DOI":"10.4161\/cbt.23761","volume":"14","author":"D Woods","year":"2013","unstructured":"Woods, D. & Turchi, J. J. Chemotherapy induced DNA damage response: convergence of drugs and pathways. Cancer Biol Ther 14, 379\u2013389 (2013).","journal-title":"Cancer Biol Ther"},{"key":"BFsrep38142_CR33","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.ctrv.2016.09.003","volume":"50","author":"R Chila","year":"2016","unstructured":"Chila, R., Guffanti, F. & Damia, G. Role and therapeutic potential of CDK12 in human cancers. Cancer Treat Rev 50, 83\u201388 (2016).","journal-title":"Cancer Treat Rev"},{"key":"BFsrep38142_CR34","doi-asserted-by":"crossref","first-page":"7265","DOI":"10.1038\/sj.onc.1206933","volume":"22","author":"ZH Siddik","year":"2003","unstructured":"Siddik, Z. H. Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene 22, 7265\u20137279 (2003).","journal-title":"Oncogene"},{"key":"BFsrep38142_CR35","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1002\/(SICI)1097-0215(19960611)66:6<779::AID-IJC12>3.0.CO;2-Z","volume":"66","author":"G Damia","year":"1996","unstructured":"Damia, G., Imperatori, L., Stefanini, M. & D\u2019Incalci, M. Sensitivity of CHO mutant cell lines with specific defects in nucleotide excision repair to different anti-cancer agents. Int J Cancer 66, 779\u2013783 (1996).","journal-title":"Int J Cancer"},{"key":"BFsrep38142_CR36","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/j.ejca.2008.01.003","volume":"44","author":"M Tavecchio","year":"2008","unstructured":"Tavecchio, M. et al. Role of homologous recombination in trabectedin-induced DNA damage. Eur J Cancer 44, 609\u2013618 (2008).","journal-title":"Eur J Cancer"},{"key":"BFsrep38142_CR37","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.ctrv.2016.05.004","volume":"48","author":"M Macerelli","year":"2016","unstructured":"Macerelli, M. et al. Can the response to a platinum-based therapy be predicted by the DNA repair status in non-small cell lung cancer? Cancer Treat Rev 48, 8\u201319 (2016).","journal-title":"Cancer Treat Rev"},{"key":"BFsrep38142_CR38","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1517\/14656566.6.12.2015","volume":"6","author":"R Garcia-Campelo","year":"2005","unstructured":"Garcia-Campelo, R., Alonso-Curbera, G., Anton Aparicio, L. M. & Rosell, R. Pharmacogenomics in lung cancer: an analysis of DNA repair gene expression in patients treated with platinum-based chemotherapy. Expert Opin Pharmacother 6, 2015\u20132026 (2005).","journal-title":"Expert Opin Pharmacother"},{"key":"BFsrep38142_CR39","unstructured":"Macerelli, M. et al. Can the response to a platinum-based therapy be predicted by the DNA repair status in non-small cell lung cancer? Cancer Treat Revin press (2014)."},{"key":"BFsrep38142_CR40","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1038\/tpj.2011.50","volume":"13","author":"E Caiola","year":"2013","unstructured":"Caiola, E. et al. DNA-damage response gene polymorphisms and therapeutic outcomes in ovarian cancer. Pharmacogenomics J 13, 159\u2013172 (2013).","journal-title":"Pharmacogenomics J"},{"key":"BFsrep38142_CR41","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1016\/j.urology.2005.12.012","volume":"67","author":"REt Browning","year":"2006","unstructured":"Browning, R. E. t. et al. ATM polymorphism IVS62+60G&gt;A is not associated with disease aggressiveness in prostate cancer. Urology 67, 1320\u20131323 (2006).","journal-title":"Urology"},{"key":"BFsrep38142_CR42","first-page":"501","volume":"9","author":"A Shin","year":"2008","unstructured":"Shin, A. et al. Genotype-phenotype relationship between DNA repair gene genetic polymorphisms and DNA repair capacity. Asian Pac J Cancer Prev 9, 501\u2013505 (2008).","journal-title":"Asian Pac J Cancer Prev"},{"key":"BFsrep38142_CR43","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1093\/hmg\/ddl033","volume":"15","author":"JH Kim","year":"2006","unstructured":"Kim, J. H. et al. Genetic polymorphisms of ataxia telangiectasia mutated affect lung cancer risk. Hum Mol Genet 15, 1181\u20131186 (2006).","journal-title":"Hum Mol Genet"},{"key":"BFsrep38142_CR44","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.lungcan.2006.12.002","volume":"56","author":"D Su","year":"2007","unstructured":"Su, D. et al. Genetic polymorphisms and treatment response in advanced non-small cell lung cancer. Lung Cancer 56, 281\u2013288 (2007).","journal-title":"Lung Cancer"},{"key":"BFsrep38142_CR45","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1038\/nrm2450","volume":"9","author":"KA Cimprich","year":"2008","unstructured":"Cimprich, K. A. & Cortez, D. ATR: an essential regulator of genome integrity. Nat Rev Mol Cell Biol 9, 616\u2013627 (2008).","journal-title":"Nat Rev Mol Cell Biol"},{"key":"BFsrep38142_CR46","first-page":"4255","volume":"128","author":"P Awasthi","year":"2015","unstructured":"Awasthi, P., Foiani, M. & Kumar, A. ATM and ATR signaling at a glance. J Cell Sci 128, 4255\u20134262 (2015).","journal-title":"J Cell Sci"},{"key":"BFsrep38142_CR47","doi-asserted-by":"crossref","first-page":"2607","DOI":"10.1016\/j.jmb.2016.02.006","volume":"428","author":"C Jeronimo","year":"2016","unstructured":"Jeronimo, C., Collin, P. & Robert, F. The RNA Polymerase II CTD: The Increasing Complexity of a Low-Complexity Protein Domain. J Mol Biol 428, 2607\u20132622 (2016).","journal-title":"J Mol Biol"},{"key":"BFsrep38142_CR48","doi-asserted-by":"crossref","first-page":"2158","DOI":"10.1101\/gad.16962311","volume":"25","author":"D Blazek","year":"2011","unstructured":"Blazek, D. et al. The Cyclin K\/Cdk12 complex maintains genomic stability via regulation of expression of DNA damage response genes. Genes Dev 25, 2158\u20132172 (2011).","journal-title":"Genes Dev"},{"key":"BFsrep38142_CR49","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/1747-1028-7-12","volume":"7","author":"J Kohoutek","year":"2012","unstructured":"Kohoutek, J. & Blazek, D. Cyclin K goes with Cdk12 and Cdk13. Cell Div 7, 12 (2012).","journal-title":"Cell Div"},{"key":"BFsrep38142_CR50","doi-asserted-by":"crossref","unstructured":"Integrated genomic analyses of ovarian carcinoma. Nature 474, 609\u2013615 (2011).","DOI":"10.1038\/nature10166"},{"key":"BFsrep38142_CR51","doi-asserted-by":"crossref","first-page":"2575","DOI":"10.1093\/nar\/gkv101","volume":"43","author":"KM Ekumi","year":"2015","unstructured":"Ekumi, K. M. et al. Ovarian carcinoma CDK12 mutations misregulate expression of DNA repair genes via deficient formation and function of the Cdk12\/CycK complex. Nucleic Acids Res 43, 2575\u20132589 (2015).","journal-title":"Nucleic Acids Res"},{"key":"BFsrep38142_CR52","doi-asserted-by":"crossref","first-page":"9247","DOI":"10.1074\/jbc.M114.551143","volume":"289","author":"PM Joshi","year":"2014","unstructured":"Joshi, P. M., Sutor, S. L., Huntoon, C. J. & Karnitz, L. M. Ovarian cancer-associated mutations disable catalytic activity of CDK12, a kinase that promotes homologous recombination repair and resistance to cisplatin and poly(ADP-ribose) polymerase inhibitors. J Biol Chem 289, 9247\u20139253 (2014).","journal-title":"J Biol Chem"},{"key":"BFsrep38142_CR53","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1158\/0008-5472.CAN-13-2541","volume":"74","author":"I Bajrami","year":"2014","unstructured":"Bajrami, I. et al. Genome-wide profiling of genetic synthetic lethality identifies CDK12 as a novel determinant of PARP1\/2 inhibitor sensitivity. Cancer Res 74, 287\u2013297 (2014).","journal-title":"Cancer Res"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/srep38142.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/srep38142","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/srep38142.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,4]],"date-time":"2023-01-04T20:36:25Z","timestamp":1672864585000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/srep38142"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,12,1]]},"references-count":53,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2016,12,23]]}},"alternative-id":["BFsrep38142"],"URL":"https:\/\/doi.org\/10.1038\/srep38142","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,12,1]]},"assertion":[{"value":"13 July 2016","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 November 2016","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 December 2016","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing financial interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"38142"}}